渤海证券研究所晨会纪要（2026.02.09）-20260209

Macro and Strategy Research - In January 2026, the central bank's liquidity net injection reached 1.2 trillion yuan, an increase of nearly 400 billion yuan compared to December 2025, indicating a supportive stance on liquidity [3] - The issuance of interest rate bonds in January 2026 totaled 2.7 trillion yuan, a year-on-year increase of over 600 billion yuan, with significant growth in government bonds, local bonds, and policy financial bonds [4] - The bond market outlook suggests that if the liquidity remains stable, interest rate bonds may show a strong oscillation pattern, with a focus on 3-year bonds and ultra-long-term bonds for potential gains [5] Industry Research - The pharmaceutical and biotechnology industry is seeing a concentration of performance forecasts, with key developments including the approval of new drugs and significant partnerships among companies [10][11] - The SW pharmaceutical and biotechnology index saw a decline of 0.97% in the week of January 30 to February 5, 2026, with the industry’s price-to-earnings ratio at 51.01 times, reflecting a 261% premium over the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, as well as monitoring companies that are expected to show a turnaround in performance [12]